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Abstract: Introduction/Objective: The efficacy of biologic therapy in the treatment of rheumatoid
arthritis (RA) has been well-established but, in practice, a quarter of patients will either not respond
to the first biologic agent or will suffer an adverse event requiring a switch to a different drug. While
clinical guidelines exist to help guide therapy and previous studies have examined sequential use of
anti-TNF agents, there is little data to inform a multiple switch strategy. Our aim was to measure the
efficacy of multiple switches of biologic in severe refractory RA. Methods: We enrolled 111 patients
whose therapy with one anti-TNF agent had failed in this open-label observational study. These
patients were all treated with a second biologic agent and 27 ultimately required treatment with
a third. The response to the therapy and disease activity were assessed at 6 and 12 months after
each switch. Results: The remission rates at 6 months were lower than previously reported and the
initiation of a second biologic agent resulted in significant improvement at 12 months, including DAS
remission in 36% of patients. The response in those receiving a third biologic was less pronounced,
as might be expected in this relatively treatment-refractory population. In this group, only patients
treated with tocilizumab had maintained remission at one year. Conclusion: Patients who do not
respond to an anti-TNF agent often benefit from being switched to a second, or even third, biologic.
Importantly, it may take longer than expected to fully assess the effectiveness of a second or third
agent in patients with refractory disease.
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1. Introduction

iations.

The treatment of rheumatoid arthritis (RA) has changed greatly in recent years due to
the introduction of biologic therapy. These agents specifically target intercellular signaling
pathways, co-stimulatory molecules, cytokines, or specific cell populations and can induce
a significant therapeutic response, leading to improved signs and symptoms of disease
as well as slowing or preventing structural damage [1]. Clinical trials and observational
studies have shown that 50–70% of RA patients respond to biological therapy, according to
ACR and EULAR criteria [2–8]. However, a significant proportion of patients will fail to
respond or have an adverse reaction to their first biologic [9–13] and require a change to an
alternative drug. With the recent approval of novel agents with differing mechanisms of
action, there are a number of treatment options available after the failure of the first biologic.
Previous studies examining the response to therapy in patients being switched from one
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agent to another have demonstrated that the efficacy and safety of the second agent is
usually comparable, or at least not markedly inferior, to initial anti-tumor necrosis factor
(anti-TNF) therapy [14–22]. Most studies to date, however, have only assessed sequential
anti-TNF therapy over relatively short time spans. The possibility of employing drugs with
different mechanism of actions, such as Il-6 blockade by tocilizumab or CD80/86–CD28
T cell co-stimulation modulator by abatacept, offers the possibility of assessing response
rates in comparison to anti-TNF inhibitors. Therefore, the primary aim of our study was
to evaluate the response rates up to one year in patients with refractory disease who had
already failed to respond to one or two anti-TNF agents and were undergoing switch to a
second or third biologic agent.
2. Materials and Methods
This was a non-interventional, open-label, “real-world” observational study. Patients
with RA were recruited from January 2015 to December 2019 from the Rheumatology Unit
in the Department of Clinical and Experimental Medicine of the University of Messina. All
RA patients fulfilled the 2010 ACR classification criteria [23].
In total, 301 biologic agent-naïve RA patients (study population) began initial therapy
with an anti-TNF agent. Of these, 111 (women: 80, men: 30; age range: 43–71) subsequently
failed to respond to the therapy (defined as persistent clinical symptoms and a DAS28 > 5.1)
and were switched to a second biologic. Then, 27 of these patients (women: 22, men: 5;
age range: 50–67) failed to respond to therapy with the second agent and were ultimately
switched to a third. The choice of agent was not restricted by protocol and was left up to the
discretion of the treating rheumatologist. Baseline data, including demographics, disease
duration, past and current use of disease-modifying anti-rheumatic drugs (DMARDs),
disease activity score in 28 joints (DAS28), and Health Assessment Questionnaire (HAQ)
were recorded prior to the initiation of the second or third biologic agent. The outcomes of
interest included the EULAR response criteria and proportion of patients achieving low
disease activity (DAS28 between 2.85 and 3.2), minimal disease activity (DAS28 between
2.6 and 2.85), and remission (DAS28 < 2.6). Patients not evaluated at 6 months were defined
as dropouts and were not included in further analyses. No additional visits or laboratory
tests were required outside of routine clinical practice. In total, 62% of patients were on
background methotrexate and 20% were on other DMARDs. The initial biologic chosen
for all patients was an anti-TNF inhibitor. Patients were followed every 10 weeks, on
average, and the goal was the remission of the disease (DAS28 < 2.6). In the majority of
patients receiving a second agent, anti-TNF therapy (infliximab, etanercept, adalimumab)
was used (54%) while abatacept (n = 24) and tocilizumab (n = 27) accounted for the
remainder. Treatment doses were: infliximab 3 mg/kg every 8 weeks iv; adalimumab
40 mg every 2 weeks sc; etanercept 50 mg every week sc; abatacept 10 mg/kg every
4 weeks iv; tocilizumab 8 mg/kg every 4 weeks iv. This study was approved by the ethics
committee of the Faculty of Medicine at the University of Messina (98–15). All patients
provided their written informed consent.
Results are expressed as mean values ± standard deviation or percentage. Student’s t-test was used in the between-group analysis and p values < 0.05 were considered
statistically significant.
3. Results
During the study period, 301 patients were initiated with a first biologic agent. Of
these, 163 patients either responded well and did not require a switch to another biologic
or they experienced an adverse event precluding the use of another biologic agent. Of the
138 patients who then received a second biologic, 27 could not be evaluated at 6 months
and were not assessed further due to treatment discontinuation or follow-up delay. The
remaining 111 patients were subsequently switched to a second agent (group I) and 36
of these were ultimately switched to a third (group II), with 9 patients lost to follow-up
due to treatment discontinuation or follow-up delay (Figure 1). The reasons for the switch
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3.1. Drug-Specific Response Rates and Disease Activity-Group I
At the 6-month follow-up, all drugs produced at least a “moderate” response in
more than half of patients in group I. The rates of “good” response ranged from 0% for
tocilizumab and infliximab to 25% for adalimumab (Table 2). At 12 months, the percentage
of patients achieving a “good” response rose for all drugs, including a rate of 100% for
infliximab. By 6 months, disease remission was achieved with 3 agents, abatacept (12.5%),
adalimumab (25%), and etanercept (9%), while at 12 months, the remission rate ranged
from 25% to 60% for all drugs (Figure 2C–G).
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Table 1. Baseline characteristics of patients included in analyses. * p < 0.001.
First Switch (Group I)

Second Switch (Group II)

54 ± 8.47

53 ± 7.93

25.02 ± 4.04

25.14 ± 4.99

Female (%)

89 (80)

22 (82)

Duration of disease (y), (mean ± SD) *

13.37 ± 6.12

27 ± 7.56

DAS28, (mean ± SD)

5.63 ± 1.30

5.33 ± 2.19

HAQ, (mean ± SD)

2.07 ± 0.50

1.94 ± 0.67

Age (y), (mean ± SD)
BMI

(Kg/m2 ),

(mean ± SD)

Concurrent corticosteroid use
None, n (%)

22 (20)

5 (19)

≤5 mg, n (%)

67 (60)

15 (56)

>5 mg, n (%)

15 (18)

6 (22)

Concurrent MTX use, n (%)

69 (62)

16 (60)

Weekly MTX dose (mg), (mean ± SD)

8.80 ± 2.40

9.2 ± 2.20

Concurrent other DMARDs use, n (%)

22 (20)

6 (22)

Table 2. Drug-specific EULAR response in both study groups. According to the EULAR criteria,
the response rates have been classified as no response, moderate and good response based on the
changes in the disease activity score in 28 joints at 6 and 12 months.
First Switch (Group I)
6 Months

12 Months

Tocilizumab (n = 24)

Second Switch (Group II)
6 Months

12 Months

Tocilizumab (n = 6)

No response, n (%)

3 (12.5)

0 (0)

0 (0)

0 (0)

Moderate response, n (%)

21 (87.5)

6 (25)

3 (50)

3 (50)

Good response, n (%)

0 (0)

18 (75)

3 (50)

3 (50)

Abatacept (n = 24)

Abatacept (n = 9)

No response, n (%)

6 (25)

0 (0)

3 (33)

0 (0)

Moderate response, n (%)

15 (62.5)

18 (75)

3 (33)

9 (100)

Good response, n (%)

3 (12.5)

6 (25)

3 (33)

0 (0)

Adalimumab (n = 12)

Adalimumab (n = 3)

No response, n (%)

0 (0)

0 (0)

2 (66)

0 (0)

Moderate response, n (%)

9 (75)

6 (50)

1 (33)

3 (100)

Good response, n (%)

3 (25)

6 (50)

0 (0)

0 (0)

Etanercept (n = 33)

Etanercept (n = 9)

No response, n (%)

0 (0)

0 (0)

9 (100)

0 (0)

Moderate response, n (%)

30 (91)

6 (18)

0 (0)

6 (66)

Good response, n (%)

3 (9)

27 (82)

0 (0)

3 (33)

Infliximab (n = 15)
No response, n (%)

0 (0)

0 (0)

Moderate response, n (%)

15 (100)

0 (0)

Good response, n (%)

0 (0)

15 (100)
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Figure 2. (A–G). DAS28 changes over time, classified in high disease activity (DAS28 > 5.1), moderate disease activity
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3.2. Drug-Specific Response Rates and Disease Activity-Group II
At 6 months, tocilizumab and abatacept produced a EULAR response of “good” in
group II in 3/6 and 3/9 patients, respectively. No other agent produced a “good” response.
At 12 months, 3/6 patients on tocilizumab and 3/9 of those on etanercept maintained
a “good” response, while those switched to adalimumab and abatacept only reached a
“moderate” response (Table 2). At the 6-month follow-up, 3/6 and 3/9 patients treated with
tocilizumab and abatacept were in remission, while at 12 months, only patients treated with
tocilizumab remained in remission. The DAS28 changes over time for group II are shown
in Figure 2B. However, the numbers were too small for statistical or graphical analysis.
Overall, functional status as assessed by HAQ scores significantly improved in both
groups at 6 and 12 months of follow-up (Table 3). In group I, infliximab, adalimumab, and
etanercept produced a HAQ < 0.5 at 12 months, while in group II, only tocilizumab elicited
this response.
Table 3. HAQ at baseline and at the 6- and 12-month assessment. Values are expressed as the
mean ± SD. * p < 0.0001.
Group I (n = 111)

Group II (n = 27)

HAQ0

2.07 (0.51)

1.94 (0.47)

HAQ6

0.98 (0.37) *

1.01 (0.46) *

HAQ12

0.53 (0.18) *

0.78 (0.37) *

4. Discussion
It is well-established that the aggressive treatment of early RA with the goal of lowdisease activity can produce higher rates of disease remission and less joint damage and
deterioration. Clinical guidelines have been published to aid practitioners in choosing
which initial agents to use in a given patient, and when to change therapy when the
desired outcome has not been achieved. In general, however, recommendations regarding
changing from one biologic to another rely on expert consensus opinion [24–26] and there
is even less data available to guide the management of patients who have failed to respond
to multiple biologic agents.
This study confirms that patients who failed to respond to the initial biologic therapy
with an anti-TNF agent may obtain a significantly beneficial response after switching to a
second, or even third, drug. Overall rates of “moderate” and “good” EULAR responses in
both groups of patients were consistent with previous studies. However, remission rates at
6 months in those patients undergoing the first switch was lower than had been previously
reported [27,28]. Karlsson et al.; for example, reported an overall remission rate of 16% in
patients undergoing the first switch at 3 months [29]. This discrepancy may be explained
by the unequal follow-up period between the two studies and, in fact, we found remission
rates of 36% in group I and 11% in group II at 12 months. In addition, all drugs (except
for abatacept) showed significantly higher rates of remission compared to the baseline in
both groups. This may suggest either regression to the mean, or that 6 months may not
be enough time to fully assess the capacity of a biologic agent to induce remission in this
relatively treatment-refractory population and that remission may still be possible even in
patients who have failed to respond to multiple biologic agents, particularly when a drug
with a different mechanism of action is used.
While the EULAR response was similar at 12 months in all patients across all biologic
agents, we did note drug-specific differences in disease activity. In those undergoing the
first switch in therapy (group I), the highest rates of remission at 12 months were seen in
patients treated with infliximab and etanercept. In those receiving abatacept, none achieved
remission and 75% continued to have moderate disease activity. This result is in contrast to
recent investigations suggesting that abatacept is specifically effective as a switch therapy
in patients who have failed to respond to an anti-TNF agent [30,31].
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In general, patients being switched to a third biologic agent would be expected to have
more severe disease and diminished response to therapy. This hypothesis was borne out as
there were, in fact, lower rates of “good” EULAR response in this population. However,
there were no patients who were completely refractory to therapy, as all showed at least
a “moderate” response to a third agent. This observation is clinically significant and
reinforces current practice. Interestingly, the only biologic able to induce remission in this
group at 12 months was tocilizumab, with 50% (3/6) of patients achieving this outcome.
This observation is in line with data published by Emery et al.; who demonstrated a 30%
remission rate in a phase 3 study of tocilizumab in patients being switched from a previous
biologic agent [32]. In contrast, all patients receiving abatacept or adalimumab and two
thirds of those treated with etanercept continued to have moderate disease activity.
Indeed, the reasons for discontinuation due to the occurrence of adverse events or
inefficacy represents a different background that orientates the choice of a subsequent
biologic agent. Thus, in larger RA studies, retention rates should be better stratified to
identify factors predisposing to “moderate” to “good” response according to the specific
reason for biologic failure.
The strength of this study lies in its “real-world” applicability. No limitations were
placed on the choice or sequence of the biologic therapy. The results, therefore, represent
a wide range of treatment decisions made in the course of usual patient care. This is
simultaneously a limitation since, in an observational study of this kind, it is not possible
to control for all confounding factors, which raises the possibility of confounding by
indication. The study physicians were free to choose any biologic agent, and disease
severity or specific patient factors may have influenced their selection. The baseline disease
activity, however, was similar in both patient groups and for each biologic agent, suggesting
that disease severity was roughly equal at the time of the therapeutic switch. In addition,
the long duration of the therapy for each agent and the lengthy timeframe of observation
would be expected to dampen the usual fluctuations in disease activity and the effects
of regression to the mean. Dropout rates were relatively high, however, this may not be
unexpected in patients with a severe disease that is resistant to multiple agents.
There are relatively few patients in group II, making it impossible to arrive at any
definitive conclusions regarding either drug efficacy or the optimal sequence of biologic use.
This small cohort, however, represents patients who have failed to respond to numerous
agents, including multiple biologics. There is little data to guide the therapy in this group
and randomized clinical trials in this patient population would be quite difficult. Our
data, while based on low numbers, suggest that changing to a drug with a different
mechanism of action is a rational approach and generate the hypothesis that tocilizumab
may be a particularly effective third- or fourth-line agent in refractory disease. More data,
greater numbers of patients, and a protocolized randomized study would be needed to
confirm this.
In summary, we have shown that a switch of therapy to a second or even third biologic
agent may be beneficial at 12 months in patients who have failed to respond to previous
treatment with an anti-TNF agent, and that a longer time course may be needed to see the
full benefit of therapy in this relatively treatment-resistant patient population. In addition,
switching to an agent with a different mechanism of action may produce a better clinical
response and tocilizumab may merit specific consideration as second- or third-line therapy.
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